Sidestepping SHP2 inhibition

Bogdan Popescu; Kevin Shannon

doi:10.1084/jem.20230082

Sidestepping SHP2 inhibition

J Exp Med. 2023 May 1;220(5):e20230082. doi: 10.1084/jem.20230082. Epub 2023 Mar 3.

Authors

Bogdan Popescu^{1

2}, Kevin Shannon^{3

4}

Affiliations

¹ Department of Medicine, University of California, San Francisco , San Francisco, CA, USA.
² Department of Hematology, Carol Davila University of Medicine and Pharmacy , Bucharest, Romania.
³ Department of Pediatrics, University of California, San Francisco , San Francisco, CA, USA.
⁴ Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco , San Francisco, CA, USA.

Abstract

Allosteric SHP2 inhibitors are a novel class of compounds that target hyperactive Ras/Mitogen Activated Protein Kinase (MAPK) signaling. In this issue of JEM, Wei et al. (2023. J. Exp. Med.https://doi.org/10.1084/jem.20221563) report a genome-wide CRISPR/Cas9 knockout screen that uncovered novel mechanisms of adaptive resistance to pharmacologic inhibition of SHP2.

Publication types

Comment

MeSH terms

CRISPR-Cas Systems* / genetics
Mitogen-Activated Protein Kinases*

Substances

Mitogen-Activated Protein Kinases